Clinical trials: Insulin
Diabetes Mellitus, Non-Insulin-Dependent
The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)
The primary objectives of the ORIGIN study were: To determine whether insulin glargine-mediated normoglycemia can reduce cardiovascular morbidity and/or mortality in people at high risk for vascular disease with either Impaired…
- Trial name
- ORIGIN (NCT00069784)
- Testing
- insulin glargine (HOE901), omega-3 polyunsaturated fatty acids (PUFA), reusable pen device for insulin injection
- Where
- 40 sites in United States, Argentina and 38 more
- Volunteers
- 12,537 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
Efficacy and Safety of Vildagliptin in Combination With Insulin in Patients With Type 2 Diabetes
Many people with type 2 diabetes cannot maintain their target blood glucose levels on a single therapy. The purpose of this study is to assess the safety and effectiveness of vildagliptin, an unapproved drug, in lowering overall…
- Trial name
- NCT00099931
- Testing
- vildagliptin
- Where
- Germany
- Volunteers
- 254 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes, Diabetes Mellitus, Type 2
A Randomised Trial Comparing Efficacy and Safety After Intensification With Either Insulin Aspart Once Daily as add-on or Changing to Basal Bolus Treatment With Insulin Degludec and Insulin Aspart in Subjects With Type 2 Diabetes Previously Treated With Insulin Degludec/Insulin Aspart Twice Daily
This trial is conducted globally. The aim of the trial is to compare efficacy of insulin degludec/insulin aspart (IDegAsp) twice daily (BID) + insulin aspart (IAsp) once daily (OD) versus basal bolus with insulin degludec (IDeg)…
- Trial name
- BOOST® (NCT01814137)
- Testing
- insulin degludec/insulin aspart, insulin degludec, insulin aspart
- Where
- 40 sites in United States, Algeria and 3 more
- Volunteers
- 40 people
- Sponsor
- Novo Nordisk A/S
Healthy Adults
Effects of a Single Oral Dose of Sweet Protein Sweelin® on Blood Glucose and Insulin Levels in Healthy Adults
The study aims to evaluate, for the first time, the post-prandial effects of a single oral administration of Serendipity Berry Sweet Protein sweelin® compared to glucose and stevia, as a commercial sweetener, in healthy adults.
- Trial name
- NCT06520293
- Testing
- Sweet Beverage
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Amai Proteins
Diabetes, Diabetes Mellitus, Type 2
A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification
Trial comparing effect and safety of insulin degludec/insulin aspart vs. insulin glargine plus insulin aspart in subjects with type 2 diabetes treated with basal insulin with or without oral antidiabetic treatment in need of…
- Trial name
- NCT02906917
- Testing
- Insulin degludec/insulin aspart, Insulin glargine, Insulin aspart
- Where
- 71 sites in United States, Algeria and 5 more
- Volunteers
- 532 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1
A Clinical Trial Comparing Efficacy and Safety of Exubera® and Humalog®
To compare efficacy and safety of Exubera® vs Humalog in patients with type 1 diabetes mellitus
- Trial name
- NCT00356421
- Testing
- Inhaled Human Insulin (Exubera®), Insulin lispro (Humalog)
- Where
- 23 sites in United States, Austria and 11 more
- Volunteers
- 58 people
- Sponsor
- Pfizer
Diabetes, Diabetes Mellitus, Type 2
Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes
This trial is conducted in Africa, Asia and North America. The aim of this trial is to compare two insulin degludec (NN1250, SIBA) formulations with each other and with insulin glargine, all in combination with metformin in…
- Trial name
- NCT00611884
- Testing
- insulin glargine, insulin degludec, metformin
- Where
- 29 sites in United States, Canada and 2 more
- Volunteers
- 245 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes Mellitis
Evaluation of Insulin Glulisine (GP40321) Compared to Insulin Glulisine (Apidra® SoloStar®) in Type 1 Diabetes Mellitus Patients
The goal of this clinical trial is to demonstrate the non-inferior immunogenicity of GP40321 compared to Apidra® SoloStar® at a concentration of 100 U/mL in type 1 diabetes mellitus patients.
- Trial name
- NCT07070752
- Testing
- GP40321, Apidra® SoloStar®, RinGlar®
- Where
- 17 sites in Russia
- Volunteers
- 224 people
- Sponsor
- Geropharm
Postprandial Hyperglycemia, Metabolic Syndrome
Effects of a Carbonated Water Enriched With Amino Acids and Chromium Picolinate (Good Idea®) on Glucose Homeostasis.
It has previously been shown in healthy subjects, that a carbonated water containing a mix of amino acids and chromium picolinate can decrease postprandial blood glucose.
- Conditions
- Postprandial Hyperglycemia, Metabolic Syndrome, Type 2 Diabetes Mellitus
- Trial name
- NCT03552315
- Testing
- Carbonated water with amino acids and chromium
- Where
- Sweden
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- DoubleGood AB
Type 1 Diabetes
Study Comparing Effectiveness of Intraperitoneal Insulin Administration to Subcutaneous Insulin Administration
The purpose of this study is to evaluate the effectiveness of insulin delivered in the peritoneum (abdomen)by an implantable pump in Type 1 diabetics.
- Trial name
- MIP310 (NCT00211536)
- Testing
- Medtronic MiniMed Implantable Pump Human Recombinant Insulin, Medtronic MiniMed Implantable Pump System, Aventis HOE21PH U400
- Where
- 5 sites in United States
- Volunteers
- 107 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes Mellitus, Type 2
Compare Two Dosing Algorithms in Insulin-Naive Patients With Type 2 Diabetes Mellitus
This randomized, multicenter, open-label, active-comparator, 2-arm, parallel-group, 6 month study with approximately 360 patients will compare the efficacy of two treatment regimens (Algorithm A versus Algorithm B) in…
- Trial name
- NCT00391209
- Testing
- simplified diabetes regimen starting with a fixed dose of Human Insulin Inhalation Powder, intensive diabetes management starting with an adjusted dose of Human Insulin Inhalation Powder
- Where
- 42 sites in United States, Argentina and 7 more
- Volunteers
- 379 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus Type 2
Economic Outcomes of EQW (Exenatide Once Weekly) vs. IG (Insulin Glargine) in T2D Patients Who Are New to Injectable Therapy
Primary objective of this study is to compare diabetes-related healthcare utilization and costs in patients initiating exenatide once weekly vs insulin glargine.
- Trial name
- NCT02843399
- Where
- United States
- Volunteers
- 15,498 people
- Sponsor
- AstraZeneca
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes
This trial is conducted in Africa, North and South America, Asia and Europe. The purpose of the trial is to compare the effect of once-weekly dosing of two dose levels of semaglutide versus insulin glargine once-daily on…
- Trial name
- SUSTAIN™ 4 (NCT02128932)
- Testing
- semaglutide, insulin glargine
- Where
- 231 sites in United States, Argentina and 13 more
- Volunteers
- 1,089 people
- Sponsor
- Novo Nordisk A/S
Metabolic Syndrome
Renal Sympathetic Denervation in Metabolic Syndrome (Metabolic Syndrome Study)
The purpose of this clinical investigation is to determine the effects of renal sympathetic denervation on insulin resistance and muscle sympathetic nerve activity in patients with metabolic syndrome.
- Trial name
- NCT01911078
- Testing
- Renal Denervation, EnligHTN™ Renal Denervation System.
- Where
- Greece
- Volunteers
- 20 people
- Sponsor
- Abbott Medical Devices
Diabetes, Diabetes Mellitus, Type 2
Safety of Treatment Initiation With Biphasic Insulin Aspart 30 in Hospitalised Patients With Type 2 Diabetes
This study is conducted in Europe. The aim of this study is to evaluate the safety and efficacy of biphasic insulin aspart (NovoMix® 30) in hospitalised patients with type 2 diabetes with the aim of intensifying their treatment.
- Trial name
- NCT01565733
- Testing
- biphasic insulin aspart 30
- Where
- Poland
- Volunteers
- 2,223 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
A Study to Assess the Efficacy and Safety of Ipragliflozin in Combination With Insulin in Subjects With Type 2 Diabetes Mellitus
The purpose of this study is to assess the efficacy (superiority to placebo) of ipragliflozin based on the changes in HbA1C, as well as its safety, in patients with type 2 diabetes mellitus in combination with an insulin…
- Trial name
- NCT02175784
- Testing
- ipragliflozin
- Where
- 8 sites in Japan
- Volunteers
- 262 people
- Sponsor
- Astellas Pharma Inc
Diabetes Mellitus, Type 2
Glucose Reduction by Early Acarbose Treatment in Basal Insulin
The purpose of this study is to evaluate the efficacy and safety of acarbose in comparison with voglibose in type 2 diabetic patients whose blood glucose levels were inadequately controlled with insulin glargine alone or in…
- Trial name
- GREAN (NCT00970528)
- Testing
- Acarbose (Glucobay, BAYG5421), Voglibose (Basen)
- Where
- 11 sites in South Korea
- Volunteers
- 124 people
- Sponsor
- Bayer
Type 1 Diabetes
Study of the Effects of XOMA 052 on Insulin Production in Subjects With Well Controlled Type 1 Diabetes
The study hypothesis is that XOMA 052 may inhibit beta-cell destruction and enhance beta-cell regeneration. The purpose of this study is to assess the effects of XOMA 052 on beta-cell function and insulin production.
- Trial name
- NCT00998699
- Testing
- Xoma 052
- Where
- 2 sites in Switzerland
- Volunteers
- 22 people
- Sponsor
- XOMA (US) LLC
Type 1 Diabetes, Type 2 Diabetes
Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
The purpose of this study is to allow patients with specific needs for inhaled insulin to continue with inhaled insulin therapy using Technosphere Insulin after Exubera was withdrawn from the market.
- Trial name
- NCT01798914
- Testing
- Technosphere Insulin Inhalation Powder
- Where
- 14 sites in United States
- Sponsor
- Mannkind Corporation
Oxidative Stress, Coronary Artery Disease
Efficacy of Pioglitazone on Myocardial Function in Patients Undergoing Coronary Stent Implantation.
The purpose of this study is to determine the effects of pioglitazone, once daily (QD), on heart functioning before, during and after stent implantation.
- Conditions
- Oxidative Stress, Coronary Artery Disease, Type 2 Diabetes
- Trial name
- NCT00771004
- Testing
- Pioglitazone
- Where
- 7 sites in Germany
- Volunteers
- 63 people
- Sponsor
- Takeda